CA3237743A1 - Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer - Google Patents

Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer Download PDF

Info

Publication number
CA3237743A1
CA3237743A1 CA3237743A CA3237743A CA3237743A1 CA 3237743 A1 CA3237743 A1 CA 3237743A1 CA 3237743 A CA3237743 A CA 3237743A CA 3237743 A CA3237743 A CA 3237743A CA 3237743 A1 CA3237743 A1 CA 3237743A1
Authority
CA
Canada
Prior art keywords
psma
ligand compound
pharmaceutically acceptable
integer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3237743A
Other languages
English (en)
French (fr)
Inventor
Zhiyuan Zhong
Jiandong Yuan
Jiangtao YANG
Zhenyuan HUANGFU
Juan Sun
Bin Xu
Lei Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Ruihe Medicine Technology Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3237743A1 publication Critical patent/CA3237743A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3237743A 2021-11-10 2022-11-09 Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer Pending CA3237743A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111329108.1 2021-11-10
CN202111329108 2021-11-10
PCT/CN2022/130833 WO2023083209A1 (zh) 2021-11-10 2022-11-09 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用

Publications (1)

Publication Number Publication Date
CA3237743A1 true CA3237743A1 (en) 2023-05-19

Family

ID=86335105

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3237743A Pending CA3237743A1 (en) 2021-11-10 2022-11-09 Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer

Country Status (9)

Country Link
US (1) US20260069725A1 (https=)
EP (1) EP4431503A1 (https=)
JP (1) JP2024544870A (https=)
KR (1) KR20240105380A (https=)
CN (1) CN118176188A (https=)
AU (1) AU2022384375A1 (https=)
CA (1) CA3237743A1 (https=)
TW (1) TW202321204A (https=)
WO (1) WO2023083209A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118221764A (zh) * 2024-03-05 2024-06-21 苏州大学 一种双靶向分子探针及其制备方法与应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN117069670B (zh) * 2023-07-31 2026-04-10 复旦大学附属华山医院 靶向psma的二聚体化合物及其衍生物和应用
CN119954773A (zh) * 2023-10-31 2025-05-09 苏州威智创科生物有限公司 Psma化合物、包含其的药物组合物及其用途
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629201B2 (en) * 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
CN114401947B (zh) * 2019-06-21 2024-11-29 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118221764A (zh) * 2024-03-05 2024-06-21 苏州大学 一种双靶向分子探针及其制备方法与应用

Also Published As

Publication number Publication date
JP2024544870A (ja) 2024-12-05
AU2022384375A1 (en) 2024-05-09
CN118176188A (zh) 2024-06-11
KR20240105380A (ko) 2024-07-05
EP4431503A1 (en) 2024-09-18
TW202321204A (zh) 2023-06-01
US20260069725A1 (en) 2026-03-12
WO2023083209A1 (zh) 2023-05-19

Similar Documents

Publication Publication Date Title
CA3237743A1 (en) Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer
JP2023546525A (ja) 前立腺特異的膜抗原を標的とする化合物及びその調製方法と応用
CN102911256B (zh) 一种放射性标记的多肽配合物及其制备方法和应用
EP0831938B1 (en) Radiolabeled peptide compositions for site-specific targeting
KR20210153037A (ko) 전립선 특이 막 항원 결합 이중 모드 방사선 추적자 및 치료법
CN116514735B (zh) 一种肽脲素衍生物、含其的药物组合物及其应用
CN112043839A (zh) 靶向转铁蛋白受体的放射性同位素标记多肽显像剂及其应用
WO2026040780A1 (zh) 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
TWI893724B (zh) 丹磺醯胺修飾的psma靶向化合物及其製備方法和應用
JP2024532521A (ja) ペプチド－尿素誘導体、それを含む医薬組成物、及びそれらの使用
CN109045313A (zh) 一种靶向her2的d型多肽放射性药物及制备方法
CN107308466B (zh) 具有肿瘤血管靶向性的多肽、分子探针及其制备方法和应用
CN118878582A (zh) 一种骨转移瘤的标记前体、探针及其制备方法与应用
CN116284236B (zh) 一种18f核素标记的生长抑素受体抑制剂探针及其制备方法和试剂盒
CN118666964A (zh) 一种靶向肿瘤pd-l1的pet示踪剂、其标记前体、制备方法和应用
EP2537834B1 (en) Polyazamacrocyclic compound, and a production method and a biomedical use therefor
CN114685608B (zh) 含有三硫醚键的环肽化合物或其衍生物、其合成方法和应用
CN107674117B (zh) Cu-64 标记的Dimer-San A环肽衍生物胰腺癌分子探针的制备方法
CN119978064B (zh) 一种靶向bcma的双环肽及其制备方法与应用
EP3724168B1 (de) Neue daza-chelatoren als liganden in der leberbildgebung
TW202540073A (zh) 靶向ｓｓｔｒ受體的放射性化合物及其用途
CN121319112A (zh) 靶向cck2r多肽配体、放射性药物及其制备方法与应用
CN117567567A (zh) 一种双聚体多肽、正电子分子探针及制备方法和应用
CN120209069A (zh) 一种可增强fap抑制剂亲和力并改善药代动力学的化合物及用途
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240911

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251031

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251031

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251031

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20251031

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251101

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20260302

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20260302

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260302